Provesica Publishes XEN-D0501 Phase 1 Data on Innovative new Medicine for Overactive Bladder

Published: Nov 23, 2011

CAMBRIDGE, UK – PROVESICA LTD, a clinical-stage urology drug development company, announced today the publication of phase 1 human clinical data on XEN-D0501, the company’s TRPV1 antagonist currently being evaluated in a phase 2 clinical study for the treatment of overactive bladder (OAB). The phase 1 study, published in the British Journal of Clinical Pharmacology1, demonstrated the drug to be safe and well tolerated at doses up to 5 mg twice daily for 14 days. A copy of the paper can be downloaded from www.provesica.com. It has previously been reported that some TRPV1 antagonists affect body temperature2. For that reason the XEN-D501 phase 1 study included a detailed assessment of the potential of the drug to raise body temperature as well as other aspects of safety and pharmacokinetics.

Back to news